Compare VOYA & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | CYTK |
|---|---|---|
| Founded | 1975 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 8.0B |
| IPO Year | 2013 | 2004 |
| Metric | VOYA | CYTK |
|---|---|---|
| Price | $75.93 | $61.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $83.64 | $82.38 |
| AVG Volume (30 Days) | 753.6K | ★ 2.1M |
| Earning Date | 02-03-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.82 | N/A |
| Revenue | ★ $8,088,000,000.00 | $87,211,000.00 |
| Revenue This Year | N/A | $346.43 |
| Revenue Next Year | $5.02 | $57.69 |
| P/E Ratio | $12.98 | ★ N/A |
| Revenue Growth | 2.91 | ★ 2609.26 |
| 52 Week Low | $52.43 | $29.31 |
| 52 Week High | $78.00 | $70.98 |
| Indicator | VOYA | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 47.26 |
| Support Level | $74.26 | $60.42 |
| Resistance Level | $76.34 | $64.43 |
| Average True Range (ATR) | 1.30 | 2.77 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 81.11 | 20.93 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.